BPC-157+TB-500 Blend Wolverine

Scientific / technical description

The Two Components
BPC-157 (Body Protection Compound-157) is frequently described in the literature as a stable gastric pentadecapeptide, a label reflecting its relative resistance to hydrolysis in aqueous and enzymatic conditions compared with many short peptides. TB-500 is a fragment-derived peptide associated with the actin-sequestering function of thymosin beta-4; in preclinical study it is referenced for its role in cytoskeletal actin dynamics and cell-migration models. Each has its own molecular weight and chromatographic signature, which is why a blend is characterized component-by-component rather than as a single peak.

BPC-157: a synthetic 15-amino-acid sequence not found intact in nature, produced synthetically and used as a model peptide in gastrointestinal, angiogenesis-related, and cell-migration research.
TB-500: a synthetic peptide corresponding to the actin-binding domain of thymosin beta-4, studied in vitro for actin-sequestration chemistry and cell-motility endpoints.
Combined preparation: both sequences supplied together as one lyophilized research material at a stated ratio, for laboratory co-formulation studies.

What Has Been Studied
The published record for each component is predominantly in-vitro and rodent-model in nature; the two are more often studied individually than as a fixed blend, so combined-preparation data remains preliminary and ongoing. Reported experimental lines of inquiry for BPC-157 include interactions with nitric-oxide (NO) system pathways, cell-migration and wound-closure scratch assays, and angiogenesis-associated endpoints such as VEGFR2 expression in cultured endothelial cells. For TB-500, laboratory work has focused on actin-monomer sequestration, cytoskeletal reorganization, and cell-migration models. These are observations in isolated cells and animal models, not outcomes in people, and cross-study generalization is not supported by current data.

Analytical Characterization
For a two-component blend, analytical verification confirms three things: the identity of each peptide, the purity of each peptide, and the ratio in which they are present. Reversed-phase HPLC (RP-HPLC) resolves the two sequences into separate peaks; peak-area integration is used to report purity and to estimate the relative proportion of each component (blend purity typically ≥98%). Mass spectrometry (ESI-MS or MALDI-TOF) confirms the observed mass of each peptide against its theoretical value, verifying that both BPC-157 and TB-500 are present and correct rather than a single sequence or a degradation product.

The lot-specific Certificate of Analysis (COA) is the definitive analytical record for the exact material received. Because purity and component ratio can vary slightly between synthesis and blending batches, researchers should reference the COA tied to the lot number in hand rather than generic specifications when documenting experimental inputs, and retain it alongside experimental records to support reproducibility and traceability.

Laboratory Handling of the Lyophilized Blend
As with other lyophilized research peptides, the blend is hygroscopic and sensitive to repeated temperature cycling. Standard laboratory practice is to allow the sealed vial to equilibrate to room temperature before opening to minimize condensation, then reconstitute with an appropriate research-grade solvent under aseptic technique so that both sequences dissolve together at the intended concentration. Aliquoting the reconstituted stock into single-use portions limits freeze-thaw cycles that can degrade peptide integrity and shift the effective ratio. Refer to the storage table on this page for temperature and stability windows. This material is for in-vitro research only and is not for human or animal use.